Pharma Company Selects OmniComm Platform
Fort Lauderdale, FL. - OmniComm Systems, Inc., a global leading provider of clinical data management technology, today announced that a global top 15 pharmaceutical organization selected TrialOne to automate its entire Phase I and BA/ BE clinic. The expressed aims are to standardize processes, improve business intelligence, ensure compliance, and achieve overall business transformation within its early phase research. TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early phase research clinics. TrialOne is the market leading eSource system for early phase research clinics that addresses the following needs of this pharmaceutical organization:
- Manage and optimize patient screening and recruitment
- Fully validated eSource from paper source records
- Implement data capture from subject bedside
- Automated data capture from medical monitoring equipment and devices
- Streamline staff training and support records
- Integration with laboratory information management systems (LIMS) for lab orders and lab results processing
TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance. “With this key additional TrialOne success, OmniComm continues to reinforce its position as the market leader in early phase clinic automation,” said Kuno van der Post, SVP of business development, OmniComm Systems. “The close interaction with our major pharmaceutical and clinical research organization (CRO) clients has driven our solution to the point that one of the key reasons we were selected was in no small part due to references from our installed user base.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit
www.omnicomm.com
.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
